XIENCE stent receives European CE Mark for one-month dual anti-platelet therapy (DAPT) for high bleeding risk patients. - Abbott

Abbott announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – for patients with high bleeding risk (HBR). The approval follows recent results from two studies that demonstrated both one-month or three-month DAPT followed by aspirin monotherapy is safe in HBR patients and is intended to improve patient outcomes and provide physicians more options to treat their patients. XIENCE is the most widely used stent worldwide and is the only stent to have evidence and data for both one-month and three-months DAPT followed by two different types of blood-thinning medication in HBR patients. Patients who receive stents are typically on DAPT regimens (aspirin and antiplatelet drugs known as P2Y12 inhibitors to prevent blood clots) for six to 12 months to support vessel healing and prevent clotting from blocking the stented vessel. However, high bleeding risk patients can experience side effects such as bleeding during prolonged courses of DAPT. Abbott's XIENCE 28 and XIENCE 901 studies show that DAPT can be safely discontinued early – as short as 28 days – with no increased risk in patient adverse events, further confirming the industry-leading safety profile of the XIENCE stent.